578
Participants
Start Date
November 20, 2015
Primary Completion Date
May 15, 2017
Study Completion Date
December 23, 2019
RTV
100 mg capsule coadministered orally with ATV or DRV once daily with food
ATV
300 mg capsule administered orally once daily with food
DRV
800 mg tablet administered orally once daily with food
COBI
150 mg tablet coadministered orally with ATV or DRV once daily with food
ATV/co
300/150 mg FDC tablet administered orally once daily with food
DRV/co
800/150 mg FDC tablet administered orally once daily with food
FTC/TDF
200/300 mg FDC tablet administered orally once daily without regard to food
ABC/3TC
600/300 mg tablet administered orally once daily with or without regard to food
B/F/TAF
50/200/25 mg FDC tablet administered orally once daily without regard to food
Rio Piedras
Brussels
Springfield
Darlinghurst
Sydney
Melbourne
Fitzroy
Prahran
Nice
Ghent
The Bronx
Berlin
Berlin
Buffalo
Philadelphia
Washington D.C.
Washington D.C.
Milan
Milan
Hamburg
Durham
Greenville
Madrid
Madrid
Huntersville
Charlotte
Málaga
Columbia
Atlanta
Augusta
Macon
Pensacola
DeLand
Vero Beach
Miami
Miami
Wilton Manors
Fort Lauderdale
West Palm Beach
Tampa
Ft. Pierce
Tours
Memphis
Louisville
Düsseldorf
Nantes
Essen
Berkley
Cologne
Bonn
Minneapolis
Tourcoing
Frankfurt
Frankfurt
Chicago
Chicago
St Louis
Kansas City
Kansas City
Lyon
New Orleans
Paris
Dallas
Dallas
Dallas
Paris
Longview
Houston
Houston
Austin
Aurora
München
München
Phoenix
Phoenix
Los Angeles
Los Angeles
Los Angeles
Torrance
San Diego
Newport Beach
San Francisco
San Leandro
Oakland
Sacramento
Honolulu
Seattle
Spokane
Orlando
Chicago
The Bronx
Santo Domingo
Boston
Chapel Hill
Annandale
Vancouver
Toronto
Toronto
Montreal
Montreal
Montreal
Roma
Ponce
San Juan
San Juan
Birmingham
Birmingham
Brighton
Edinburgh
Liverpool
London
London
London
London
London
London
London
Manchester
Manchester
Lead Sponsor
Gilead Sciences
INDUSTRY